Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 01:55PM ET
21.33
Dollar change
-0.16
Percentage change
-0.73
%
Index- P/E- EPS (ttm)-1.64 Insider Own0.24% Shs Outstand26.84M Perf Week-2.13%
Market Cap572.50M Forward P/E6.72 EPS next Y3.18 Insider Trans0.00% Shs Float26.77M Perf Month-2.51%
Income-43.98M PEG- EPS next Q-0.16 Inst Own3.15% Short Float0.03% Perf Quarter-25.16%
Sales113.46M P/S5.05 EPS this Y122.06% Inst Trans- Short Ratio0.75 Perf Half Y14.80%
Book/sh1.24 P/B17.23 EPS next Y759.77% ROA-23.54% Short Interest0.01M Perf Year-4.78%
Cash/sh3.60 P/C5.93 EPS next 5Y- ROE-82.38% 52W Range15.25 - 29.30 Perf YTD-17.15%
Dividend Est.- P/FCF- EPS past 5Y-22.85% ROI-34.06% 52W High-27.20% Beta1.51
Dividend TTM- Quick Ratio3.08 Sales past 5Y7065.62% Gross Margin94.99% 52W Low39.87% ATR (14)0.86
Dividend Ex-Date- Current Ratio3.13 EPS Y/Y TTM-0.76% Oper. Margin-34.67% RSI (14)46.95 Volatility2.21% 3.40%
Employees178 Debt/Eq2.89 Sales Y/Y TTM48.36% Profit Margin-38.76% Recom1.25 Target Price45.59
Option/ShortYes / Yes LT Debt/Eq2.89 EPS Q/Q-397.67% Payout- Rel Volume0.05 Prev Close21.49
Sales Surprise29.06% EPS Surprise63.87% Sales Q/Q5.81% EarningsFeb 21 BMO Avg Volume9.73K Price21.33
SMA20-2.28% SMA50-2.10% SMA20010.87% Trades Volume398 Change-0.73%
Date Action Analyst Rating Change Price Target Change
Jun-20-23Initiated H.C. Wainwright Buy $60
Mar-01-23Initiated Guggenheim Neutral $18
Feb-26-21Initiated H.C. Wainwright Buy $52
Jul-01-20Initiated Citigroup Buy $36
Jun-30-20Initiated Jefferies Buy $44
Mar-11-24 09:28PM
Mar-06-24 02:34AM
Mar-01-24 07:39AM
Feb-22-24 11:15AM
Feb-21-24 01:45AM
01:11AM Loading…
Feb-14-24 01:11AM
Feb-13-24 11:26AM
Jan-08-24 02:31AM
Jan-07-24 11:19AM
11:05AM
Dec-27-23 12:16PM
Dec-20-23 09:30PM
04:33PM
Dec-11-23 09:38AM
Dec-01-23 03:21AM
02:49AM Loading…
Nov-30-23 02:49AM
Nov-24-23 03:10AM
Nov-07-23 10:29AM
01:32AM
Nov-06-23 08:00PM
Oct-27-23 03:27AM
Oct-23-23 09:33AM
Oct-19-23 03:58AM
Oct-05-23 04:42AM
Oct-04-23 07:30PM
Oct-03-23 04:20AM
Sep-29-23 08:17AM
Sep-28-23 06:22AM
Sep-27-23 01:33PM
Sep-19-23 10:37AM
08:20PM Loading…
Aug-20-23 08:20PM
Aug-18-23 04:21AM
Aug-17-23 08:40PM
01:34AM
Aug-15-23 04:52AM
Jul-13-23 02:20AM
Jun-21-23 04:12AM
May-30-23 10:18AM
May-16-23 01:14AM
May-05-23 09:01AM
Apr-28-23 04:54AM
Apr-26-23 10:40PM
Apr-11-23 09:43AM
Mar-31-23 11:24AM
Mar-13-23 01:15PM
Mar-12-23 11:15PM
Feb-23-23 01:41AM
Feb-02-23 03:46AM
Jan-31-23 02:22AM
Dec-30-22 03:03AM
02:16AM
Dec-20-22 10:08PM
Dec-13-22 03:04AM
Dec-09-22 02:10AM
Nov-15-22 02:45AM
Nov-14-22 01:11AM
Nov-07-22 03:15AM
Oct-21-22 09:12AM
04:27AM
Oct-19-22 10:09AM
Sep-20-22 09:29AM
Aug-18-22 01:16AM
Aug-15-22 09:55AM
Jul-29-22 06:26AM
Jul-28-22 09:55AM
Jul-17-22 08:00PM
Jul-15-22 11:19AM
Jul-11-22 07:00AM
Jul-07-22 08:00AM
Jun-30-22 04:35AM
Jun-28-22 06:26PM
Jun-03-22 08:00AM
May-19-22 03:21PM
10:46AM
08:41AM
May-18-22 01:30AM
May-17-22 05:18AM
May-14-22 08:00AM
May-10-22 02:43AM
Apr-29-22 04:18AM
Apr-27-22 12:13PM
Apr-14-22 03:30AM
Mar-24-22 07:11AM
Mar-22-22 03:09PM
08:02AM
Mar-18-22 03:19AM
Mar-14-22 02:24AM
Mar-13-22 08:00PM
Feb-24-22 04:41AM
Feb-15-22 04:40AM
Jan-28-22 02:16AM
Dec-16-21 09:26AM
08:40AM
07:52AM
06:26AM
Dec-15-21 05:05PM
Nov-18-21 01:21AM
Nov-03-21 04:42AM
Nov-02-21 05:17AM
Oct-07-21 06:32AM
Calliditas Therapeutics AB clinical-stage biopharmaceutical company. It engages in the identification, development, and commercialization of novel treatments in orphan indications. The firm focuses on renal and hepatic diseases with significant unmet medical needs. It offers Nefecon, a proprietary, novel oral formulation of budesonide for the treatment of the autoimmune renal disease IgA nephropathy, or IgAN. The firm product TARPEYO is used to reduce proteinuria in adults with primary immunoglobulin. The company was founded by Mikael Bender and Bengt Ake Julander on February 20, 2004 and is headquartered in Stockholm, Sweden.